Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP410511.RAIIodsYs0EW3MxN4iU5bnRhwEy2Fplka7iAu2aBJiSMU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP410511.RAIIodsYs0EW3MxN4iU5bnRhwEy2Fplka7iAu2aBJiSMU130_assertion type Assertion NP410511.RAIIodsYs0EW3MxN4iU5bnRhwEy2Fplka7iAu2aBJiSMU130_head.
- NP410511.RAIIodsYs0EW3MxN4iU5bnRhwEy2Fplka7iAu2aBJiSMU130_assertion description "[An ongoing phase II, double blind, placebo-controlled study is evaluating farletuzumab in patients with FOLR1 expressing metastatic adenocarcinoma of lung.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP410511.RAIIodsYs0EW3MxN4iU5bnRhwEy2Fplka7iAu2aBJiSMU130_provenance.
- NP410511.RAIIodsYs0EW3MxN4iU5bnRhwEy2Fplka7iAu2aBJiSMU130_assertion evidence source_evidence_literature NP410511.RAIIodsYs0EW3MxN4iU5bnRhwEy2Fplka7iAu2aBJiSMU130_provenance.
- NP410511.RAIIodsYs0EW3MxN4iU5bnRhwEy2Fplka7iAu2aBJiSMU130_assertion SIO_000772 23357463 NP410511.RAIIodsYs0EW3MxN4iU5bnRhwEy2Fplka7iAu2aBJiSMU130_provenance.
- NP410511.RAIIodsYs0EW3MxN4iU5bnRhwEy2Fplka7iAu2aBJiSMU130_assertion wasDerivedFrom befree-20150227 NP410511.RAIIodsYs0EW3MxN4iU5bnRhwEy2Fplka7iAu2aBJiSMU130_provenance.
- NP410511.RAIIodsYs0EW3MxN4iU5bnRhwEy2Fplka7iAu2aBJiSMU130_assertion wasGeneratedBy ECO_0000203 NP410511.RAIIodsYs0EW3MxN4iU5bnRhwEy2Fplka7iAu2aBJiSMU130_provenance.